Loading...
•
Mar 31
Anavex Q2 2025 Earnings Report
Reported financial results for the second quarter of fiscal 2025
Key Takeaways
Anavex Life Sciences reported a net loss of $11.2 million for the second quarter of fiscal 2025, compared to a net loss of $10.5 million in the same period last year. The company's cash and cash equivalents stood at $115.8 million as of March 31, 2025.
Net loss for the second quarter of fiscal 2025 was $11.2 million.
Basic and diluted net loss per share was $0.13 for the quarter.
Cash and cash equivalents were $115.8 million at March 31, 2025.
The company expects approximately 4 years of cash runway at current utilization rates.
Anavex
Anavex
Forward Guidance
Anavex expects to report top-line data from the Phase 2 study of ANAVEX®3-71 for schizophrenia in the second half of 2025.
Positive Outlook
- Completion of enrollment in the Phase 2 clinical study of ANAVEX®3-71 for schizophrenia.
- Encouraging preliminary safety and EEG biomarker results reported from Part A of the ANAVEX®3-71 study.
- Long-term data from the ATTENTION-AD Open-Label-Extension trial showed continued clinically meaningful benefit for early Alzheimer’s disease patients treated with blarcamesine.
- Blarcamesine-treated patients showed continued benefit through up to 4 years in clinical endpoints.
- Appointment of a specialist in predictive, personalized medicine and digital health in Alzheimer' disease to the Scientific Advisory Board.
Challenges Ahead
- Top-line data from the ANAVEX®3-71 study is not expected until the second half of 2025.
- Net loss increased compared to the same quarter in the previous fiscal year.
- Cash and cash equivalents decreased compared to the year ended September 30, 2024.
- No specific forward guidance on revenue or profitability was provided.
- The report focuses on clinical trial progress rather than near-term financial performance improvements.